Spotlight Medical Announces Publication in Journal of Clinical Oncology Validating AI Pathology Assay That Identifies Low-Risk Subgroup Within Clinically High-Risk Early ER+/HER2- Breast Cancer

The assay identifies a biologically low-risk subgroup within clinically high-risk patients, with outcomes similar to stage I disease, potentially sparing 30,000 women each year from unnecessary treatment intensification